High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of
palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk
ER-positive/HER2-negative T1-2N0-1 EBC(Early Breast Cancer)